Premium
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine‐refractory chronic lymphocytic leukemia
Author(s) -
Ferrajoli Alessandra,
Wierda William G.,
LaPushin Ruth,
O’Brien Susan M.,
Faderl Stefan,
Browning Mary L.,
Keating Michael J.
Publication year - 2008
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2007.01023.x
Subject(s) - alemtuzumab , fludarabine , medicine , chronic lymphocytic leukemia , refractory (planetary science) , tolerability , continuous infusion , gastroenterology , population , oncology , leukemia , chemotherapy , adverse effect , transplantation , cyclophosphamide , environmental health , physics , astrobiology
We evaluated the activity and tolerability of alemtuzumab given as a continuous infusion for 7 d followed by subcutaneous administration for 11 wk as salvage therapy for 10 patients with fludarabine‐refractory chronic lymphocytic leukemia. The continuous infusion of alemtuzumab was well tolerated. The typical infusion reaction seen with intravenous alemtuzumab was abolished. Two patients achieved a partial response with an overall response rate of 20%. Alemtuzumab levels were measured in four patients and detectable levels were obtained in three. Clinical activity needs to be confirmed in a larger patient population.